

# EJC Supplements

## The Use of Taxanes in Early Breast Cancer

*Opinions expressed in this supplement are those of the author, and do not necessarily reflect those of  
Bristol-Myers Squibb Company, Oncology Division, Europe.*

*In Europe, in breast cancer Taxol<sup>®</sup> (paclitaxel) is currently indicated for the treatment of metastatic carcinoma of the breast in patients who have failed, or are not candidates for standard, anthracycline-containing therapy. In Europe, Taxol<sup>®</sup> is also approved in combination with trastuzumab for the initial treatment of advanced or metastatic breast cancer in patients who overexpress HER2 at the 3+ level, as determined by immunohistochemistry, and for whom an anthracycline is not suitable.*

*In breast cancer Taxol<sup>®</sup> is approved for use at a dose of 175 mg/m<sup>2</sup> in a 3-hour infusion every 3 weeks.*

*Please see the Taxol<sup>®</sup> Summary of Product Characteristics for more information.*

*In Europe, Taxol<sup>®</sup> is also indicated in the treatment of first-line (in combination with cisplatin) and second-line chemotherapy (after failure of standard, platinum-containing therapy) of ovarian cancer, and in combination with cisplatin in the treatment of patients with non-small cell lung cancer who are not candidates for potential surgery and/or radiotherapy.*



PERGAMON



1359-6349(200310)1:7;1-U